triple glp 1 gip glucagon receptor agonist LY3437943, a novel glucagon, GIP, and GLP-1 for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Targeting GLP-1, GIP & GCG

Drugs like Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda, Victoza) are not only changing the way we manage Type 2 Diabetes but also making waves in the weight-loss industry

People Going Blind From GLP-1: Risks, Evidence and Protection Recent reports have raised concerns about potential links between GLP-1 medications and vision problems, prompting questions about whether people are going blind from GLP-1 treatments

Danuglipron Danuglipron is a small-molecule GLP-1 receptor agonist, formerly under development by Pfizer [1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus

Designing these solutions is extremely non-trivial

doi: 10.3389/fcell.2020.593269

TG, Trigrlyceride